We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Diseases of liverDiabetes mellitus
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Non-alcoholic fatty liver disease (NAFLD) is the commonest chronic liver disease worldwide and affects up to three quarters of people living with type 2 diabetes. In most people with NAFLD, build up of fat in the liver (simple steatosis) does not cause harm. However in up to 19% of cases, fat damages liver cells and causes inflammation and scarring of the liver. This is called non-alcoholic steatohepatitis or NASH for short. Over time, NASH can cause cirrhosis, which can lead to liver failure, cancer or death, and people with type 2 diabetes are at particular risk of this progression, but we do not fully understand why.
Apart from performing a liver biopsy, there is currently no accurate way to distinguish patients who have NASH from those with simple steatosis. NASH is characterised by presence of steatosis, damaged liver cells leading to scar formation (fibrosis) and immune cells. The nature and function of immune cells in the liver in NASH are largely unknown as is their relationship to immune cells in the peripheral blood and adipose tissue. Other than the liver, adipose tissue is the main site where excess dietary fats are stored in the body. Studies in obesity have demonstrated presence of inflammatory immune cells in adipose tissue, but at present, we do not know how these immune cells contribute to the pathogenesis of NASH, nor whether immune cells from different body compartments have similar function and origin.
The aim of this project is analyse liver, adipose tissue and blood samples from NAFLD patients undergoing bariatric surgery to map out and determine the relationships between immune cells in the liver, adipose tissue and peripheral blood in patients with different stages NAFLD and thus determine the mechanistic role of immune cells in this disease process.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
Unwilling or unable to give informed consent Non-type II Diabetes Mellitus Use of GLP-1 or GIP agonists Other form of liver disease (other than NAFLD): Viral hepatitis, Auto-immune hepatitis, primary sclerosing cholangitis, primary biliary cholangitis, haemochromatosis, Sarcoidosis, cystic fibrosis, sickle cell disease Taking medication associated with liver dysfunction (except methotrexate) Auto-immune disease which in the investigator’s opinion may confound immune profiling Concomitant immunosuppressive medications (except methotrexate, short course oral steroids or inhaled corticosteroids) Currently pregnant Any major organ transplant (excluding corneal or hair transplant) Regular alcohol intake greater than 14 units a week for female participants and 21 units a week for male participants
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by Queen Mary University of London and funded by Medical Research Council (MRC) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 51830
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
